In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers
For people with MS, this means it can be helpful to: Decisions about how long to use a GLP-1 medication are highly individual and best made through ongoing conversations with your healthcare provider
AP events were predominantly reported for unknown indications (53.8%) and T2DM (43.0%)
Diabetes 52(2):380386 Latif W, Lambrinos KJ, Rodriguez R (2021) Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs) Latif W, Lambrinos KJ, Rodriguez R (2023) Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)
What Is AOD 9604 Peptide and Why Is It Generating Clinical Interest
Ipamorelin is reported in smaller studies to cause fewer cortisol and prolactin side effects compared to older GHRP secretagogues like GHRP-6